Trial Profile
A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study of NovoRapid (Insulin Aspart) in Patients With Coexisting Diabetes and Kidney Disease in India. The NovoRapid Nephropathy Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Feb 2009 New trial record